{"id":535476,"date":"2021-09-08T08:04:26","date_gmt":"2021-09-08T12:04:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/"},"modified":"2021-09-08T08:04:26","modified_gmt":"2021-09-08T12:04:26","slug":"werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/","title":{"rendered":"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Sept.  08, 2021  (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15.<\/p>\n<p align=\"justify\">Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, will provide an overview of the company, which will be available on-demand beginning September 13 at 7:00 am EDT and will be archived for 90 days. A link to the webcast will be available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8iI2-K2sPp-AarueBDK7VYcWCADdZqlfeHuAsniDZfZbST3m_HgQE4sP5U7pYJkYkqF5IzH6Wirq947qqzfBXu_B08hynq85IXSlmmahnWl8cizTlPWduu3CcUXOyjeMmB299leblCCp98mQLSwRE2oaQx4SQ-QGjor9fU7ZV2Sm63eXC9obdJ8L2258PHZU\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.werewolftx.com\/news-and-events\/events<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Werewolf Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR\u2122 platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE\u2122 molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.<\/p>\n<p align=\"justify\">To learn more visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rBULEEvcdj4bhNh9jJ_weBkOmCJ1N4Sjfc57gJ89_1Ix00xFGnmWH249w09HLwo2aYHxynTZyu4_4XYALcTHA-EV7nJ1LfrTsPcM7eWGaH4=\" rel=\"nofollow noopener\" target=\"_blank\">www.werewolftx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Ellen Lubman<br \/>Chief Business Officer<br \/>Werewolf Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KbsbTsacvAF7h9APPHhDvkSKskPc8KXNqi1cxTIHJbupwmSPDT6-mZoPnE4u0i_AoCwNbv4l-E50BA5dbR3cIvno6Ntn9IdUZyBvv8D9Z1g=\" rel=\"nofollow noopener\" target=\"_blank\">elubman@werewolftx.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Amanda Sellers<br \/>VERGE Scientific Communications <br \/>301.332.5574<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HPvMcDkjhkAidfrnWFmJ8lY0Zb7BkHLlGMeyH4qaIp1cR85cX59k8qIurK8diNEwIcJ2BssaP8jcDkSgciPpbJcgUA7lbmlHTPNJVfPHrPEXMlxw5nliGRtrza5NH9vG\" rel=\"nofollow noopener\" target=\"_blank\">asellers@vergescientific.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NjI4NDc3ZmMtZTgxOC00MmU0LTk0MzItMWNhNDU5NzQ3NGUyLTEyMTkzMDA=\/tiny\/Werewolf-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15. Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, will provide an overview of the company, which will be available on-demand beginning September 13 at 7:00 am EDT and will be archived for 90 days. A link to the webcast will be available at https:\/\/investors.werewolftx.com\/news-and-events\/events. About Werewolf Therapeutics, Inc. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535476","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15. Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, will provide an overview of the company, which will be available on-demand beginning September 13 at 7:00 am EDT and will be archived for 90 days. A link to the webcast will be available at https:\/\/investors.werewolftx.com\/news-and-events\/events. About Werewolf Therapeutics, Inc. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to &hellip; Continue reading &quot;Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T12:04:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference\",\"datePublished\":\"2021-09-08T12:04:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/\"},\"wordCount\":278,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/\",\"name\":\"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc=\",\"datePublished\":\"2021-09-08T12:04:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15. Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, will provide an overview of the company, which will be available on-demand beginning September 13 at 7:00 am EDT and will be archived for 90 days. A link to the webcast will be available at https:\/\/investors.werewolftx.com\/news-and-events\/events. About Werewolf Therapeutics, Inc. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to &hellip; Continue reading \"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T12:04:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference","datePublished":"2021-09-08T12:04:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/"},"wordCount":278,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/","name":"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc=","datePublished":"2021-09-08T12:04:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTgwNCM0MzkzNjk2IzIyMDc3NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535476"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535476\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}